(Q42613611)

English

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

scientific article published on 17 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Andreas Hochhaus

2

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Richard A. Larson

13

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

object named as

Ian W Flinn

5

0 references

Giuseppe Saglio

object named as

Giuseppe Saglio

3

0 references

Hagop Kantarjian

1

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Gianantonio Rosti

8

object named as

Gianantonio Rosti

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Rick E Blakesley

12

object named as

Rick E Blakesley

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

6

object named as

Leif Stenke

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Carmino Antônio de Souza

4

object named as

Carmino De Souza

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Albert Hoenekopp

11

object named as

Albert Hoenekopp

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

author name string

Yeow-Tee Goh

7

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Hirohisa Nakamae

9

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Neil J Gallagher

10

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Timothy P Hughes

14

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

841-851

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Harmonization of molecular monitoring of CML therapy in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using str

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970201-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70201-7

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42613611&oldid=2193459141"